Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H040

UPID:
SPRTN_HUMAN

ALTERNATIVE NAMES:
DNA damage protein targeting VCP; Protein with SprT-like domain at the N terminus

ALTERNATIVE UPACC:
Q9H040; B1AKT0; B5MEF7; Q5TE78; Q6UWW6; Q96BC5; Q96KA0

BACKGROUND:
SPRTN is a DNA-dependent metalloendopeptidase essential for genomic integrity, acting by cleaving DNA-protein cross-links during DNA synthesis. It is involved in various critical processes, including the activation of CHEK1 during normal DNA replication and the recruitment of VCP/p97 to DNA damage sites. Its ability to interact with ubiquitinated PCNA and RAD18 highlights its multifaceted role in DNA repair mechanisms.

THERAPEUTIC SIGNIFICANCE:
The involvement of SPRTN in Ruijs-Aalfs syndrome, a condition marked by genomic instability and a predisposition to early onset hepatocellular carcinoma, underscores its therapeutic potential. Exploring SPRTN's functions and mechanisms could lead to groundbreaking therapeutic strategies targeting genomic integrity disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.